Kidney Disease

81-96 of 148

Introduction on tackling cardiorenal risk in diabetes
Introduction on tackling cardiorenal risk in diabetes
Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia
Introduction on tackling cardiorenal risk in diabetes
Prof. Melanie Davies, MD
- Prof. Melanie Davies, MD
Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes
Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes
Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia
Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes
Prof. Melanie Davies, MD; Prof. Nikolaus Marx, MD
- Prof. Melanie Davies, MD
- Prof. Nikolaus Marx, MD
SGLT2i: Overview of recent trials and guideline recommendations
SGLT2i: Overview of recent trials and guideline recommendations
Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia
SGLT2i: Overview of recent trials and guideline recommendations
Prof. Nikolaus Marx, MD
- Prof. Nikolaus Marx, MD
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
ESC 2021
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
Prof. Stefan Anker, MD, PhD
- Prof. Stefan Anker, MD, PhD
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
ESC 2021
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Prof. Frank Ruschitzka, MD
- Prof. Frank Ruschitzka, MD
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
ESC 2021
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
Prof. Rudolf de Boer
- Prof. Rudolf de Boer
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
ESC 2021
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
Kevin Damman, MD, PhD
- Kevin Damman, MD, PhD
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
ESC 2021
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
Milton Packer, MD
- Milton Packer, MD
Another chapter in the SGLT2i book
Another chapter in the SGLT2i book
ESC 2021
Another chapter in the SGLT2i book
Prof. Rudolf de Boer
- Prof. Rudolf de Boer
Where do GLP-1RA fit in in current and future management of CKD?
Where do GLP-1RA fit in in current and future management of CKD?
GLP-1RA in DKD: A new preventive challenge
Where do GLP-1RA fit in in current and future management of CKD?
Frederik Persson, MD
- Frederik Persson, MD
Treatment goals for patients with T2DM and CKD
Treatment goals for patients with T2DM and CKD
SGLT2i in CKD: How to overcome clinical inertia?
Treatment goals for patients with T2DM and CKD
Prof. Peter Rossing, MD
- Prof. Peter Rossing, MD
How can GLP-1RA benefit a patient with diabetes and CKD?
How can GLP-1RA benefit a patient with diabetes and CKD?
GLP-1RA in DKD: A new preventive challenge
How can GLP-1RA benefit a patient with diabetes and CKD?
Daniël van Raalte, MD, PhD
- Daniël van Raalte, MD, PhD
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
SGLT2i in CKD: How to overcome clinical inertia?
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
Alice Cheng, MD
- Alice Cheng, MD
Prevention strategies in patients with CKD and T2DM
Prevention strategies in patients with CKD and T2DM
GLP-1RA in DKD: A new preventive challenge
Prevention strategies in patients with CKD and T2DM
Ofri Mosenzon, MD
- Ofri Mosenzon, MD
Clinical inertia in CKD - What is the rationale for SGLT2i?
Clinical inertia in CKD - What is the rationale for SGLT2i?
SGLT2i in CKD: How to overcome clinical inertia?
Clinical inertia in CKD - What is the rationale for SGLT2i?
Janaka Karalliedde, MD, PhD
- Janaka Karalliedde, MD, PhD
Kidney benefit by SGLT2i may be mediated by hematocrit
Kidney benefit by SGLT2i may be mediated by hematocrit
Kidney Disease
Kidney benefit by SGLT2i may be mediated by hematocrit
Prof. Christoph Wanner
- Prof. Christoph Wanner

6/10